Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index; 13 of the 30 sources its claims cite were checked for support.
Abstract
New fecal microbiota for cancer patients: The composition of the gut microbiome influences the response of cancer patients to immunotherapies. Baruch et al. and Davar et al. report first-in-human clinical trials to test whether fecal microbiota transplantation (FMT) can affect how metastatic melanoma patients respond to anti–PD-1 immunotherapy (see the Perspective by Woelk and Snyder). Both studies observed evidence of clinical benefit in a subset of treated patients. This included increased abundance of taxa previously shown to be associated with response to anti–PD-1, increased CD8 + T cell activation, and decreased frequency of interleukin-8–expressing myeloid cells, which are involved in immunosuppression. These studies provide proof-of-concept evidence for the ability of FMT to affect immunotherapy response in cancer patients. Science , this issue p. 602 , p. 595 ; see also p. 573
Overview
CoChat Summary
TL;DR
In a single-arm trial, fecal microbiota transplantation (FMT) from anti–PD-1 responders plus pembrolizumab was well tolerated and produced clinical benefit in 6 of 15 evaluable patients with PD-1–refractory melanoma. Responders showed donor microbiome implantation, increased CD8+ T cell activation, and reduced IL-8–expressing myeloid cells.
Key findings
- Among 15 evaluable patients, objective responses occurred in 3 (20%: one complete response, two partial responses), and durable stable disease lasting >12 months occurred in another 3 (20%), for clinical benefit in 6 of 15. Median progression-free survival and overall survival were 3.0 and 7.0 months overall, and 14.0 and 14.0 months in the six patients with disease control.
- FMT caused durable gut microbiota perturbation; responders’ microbiota shifted toward donor composition, whereas nonresponders were heterogeneous. Responders also had greater donor bacteria–specific IgG responses and enrichment of taxa previously linked to anti–PD-1 response, including Firmicutes and Actinobacteria, with decreases in Bacteroidetes.
- Responders showed higher post-treatment CD56+CD8+ T cells, increased CD8+ T cell activation/differentiation markers, and more granzyme B–expressing MAIT cells. Tumor single-cell RNA sequencing showed fewer myeloid cells and regulatory T cells in responders, with lower myeloid CXCL8/IL-8 and SPP1 expression.
- Serum profiling showed responders had decreased circulating CCL2, CXCL8/IL-8, IL-18, IL-12p70, and IFN-γ, and increased IL-21, CXCL13, type II cytokines, and TNF-family cytokines. Metabolomic/lipidomic changes included more efficient primary-to-secondary bile acid conversion and altered triacylglycerol/monoacylglycerol/diacylglycerol levels. A transkingdom network of 371 nodes and 819 edges linked microbial taxa to host metabolomic and proteomic features.
Methods
- Single-arm clinical trial (NCT03341143) in patients with metastatic melanoma primary refractory to anti–PD-1. Sixteen patients were enrolled; 15 received colonoscopic FMT from seven anti–PD-1 responder donors plus pembrolizumab and were evaluable for response.
- Serial blood and stool sampling was performed, with infectious screening for 32 agents before FMT. Response was assessed by RECIST v1.1 every 12 weeks.
- Analyses included shotgun metagenomic sequencing of 223 fecal samples from recipients and donors, multiparameter flow cytometry of PBMCs, single-cell RNA sequencing of 64,340 CD45+ cells from 17 tumor samples, serum cytokine/chemokine profiling, metabolomics/lipidomics, and transkingdom network analysis.
Limitations
- The paper states that findings are preliminary and warrant evaluation in a larger randomized clinical trial; it also notes that insufficient tumor tissue was available to assess tumor mutation burden, PD-L1 expression, or IFN-γ gene expression signature as predictors of outcome.
- The text makes evident that the study is small and single-arm, limiting causal inference and comparison with standard-of-care outcomes; some analyses, such as the speed of microbiome change, did not reach statistical significance, which the authors attribute to limited sample size.
- The text also makes evident heterogeneity in nonresponders’ donor microbiota implantation and notes that nonresponse may reflect patient immunodeficiency, lack of tumor immunogenicity, absence of necessary taxa in the FMT, or failure of FMT implantation.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
6 Valid · 0 Not valid · 5 Not checked · 45 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“the gut microbiome is a major tumor-extrinsic regulator of responses to anti–PD-1 (6–9).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [6] Dzutsev A, Goldszmid RS, Viaud S, Zitvogel L, Trinchieri G, Eur. J. Immunol 45, 17– 31 (2015). 25328099 sourceExperimental — accuracy not yet measured
In 'The commensal microbiota controls the response to cancer therapy' our copy confirms that the gut microbiota modulates responses to cancer immunotherapy, chemotherapy, TBI and adoptive T-cell transfer (via myeloid-cell conditioning; see also Fig. 2 legend in Concluding remarks). But for checkpoint blockade the paper states only a hypothesis: after noting progress with anti-CTLA-4/anti-PD-1 antibodies [107], it says the data 'suggest the possibility that the microbiota may also modulate the clinical effectiveness of this new class of anticancer drugs.' The citing sentence therefore presents as an established, major regulator of anti-PD-1 responses what this source explicitly hedges as a suggested possibility, and no anti-PD-1 microbiome experiment is reported in our copy. (LLM, conf=0.78)
- Not checked yetcites [7] Finlay BB, Nat. Rev. Immunol 20, 522– 528 (2020). 32661409 source
- Partly supportedcites [8] Goldszmid RS, Cancer Immunol. Res 3, 103– 109 (2015). 25660553 PMC4324508 sourceExperimental — accuracy not yet measured
In 'Impact of commensal microbiota on cancer therapy' our copy states that 'The gut microbiota influences the response to cancer immunotherapy and chemotherapy by affecting the differentiation and functions of myeloid cells in the tumor microenvironment', and documents microbiota/antibiotic effects on CpG-ODN plus anti-IL10R, cyclophosphamide, oxaliplatin, TBI and adoptive CD8+ T-cell transfer — so the tumor-extrinsic, myeloid-priming part of the claim is supported. However, PD-1 appears only in 'Clinical perspectives' as one of the successful checkpoint approaches ('inhibition of immune checkpoints, such as CTLA-4 and PD-1/PD-L1/2'), with no linkage to microbiota; the paper instead only speculates that 'the variable response to cancer therapy observed in patients may be in part due to different microbiota composition'. Searches for 'anti-PD-1', checkpoint-blockade response and microbiota-control-of-checkpoint-efficacy returned no passage tying the microbiome to anti–PD-1 outcomes, so the specific anti–PD-1 qualifier of the claim is not supported by this source (it likely rests on the other references in the cluster 6–9). (LLM, conf=0.72)
- Could not verifycites [9] Zarour HM, Clin. Cancer Res 22, 1856– 1864 (2016). 27084739 PMC4872712 sourceExperimental — accuracy not yet measured
Our copy of Zarour (2016) is complete and discusses tumor-extrinsic drivers of anti-PD-1 response only in terms of the tumor microenvironment: soluble mediators (IL-10, IDO, VEGF-A, adenosine/A2aR, CSF-1R), suppressive cells (Tregs, TAM/MDSC), metabolic checkpoints (hypoxia/HIF-1α) and mutational/neoepitope burden correlating with clinical response (Therapeutic Strategies section). No passage mentions the gut microbiome, microbiota, or antibiotics; searches for 'gut microbiome/microbiota regulates response to anti-PD-1', 'microbiota composition antibiotic impact immunotherapy efficacy tumor-extrinsic', and 'bacterial composition fecal transplant' returned only TME-related and reference-list passages. The paper therefore neither supports nor contradicts the attributed claim. (LLM, conf=0.72)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“suggesting that successful implantation and mucosal trans-location of the transplanted bacteria, known to induce an IgG response against commensal bacteria, may preferentially occur in Rs (18).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant induces persistent perturbation of recipients’ gut microbiome
What the sources say
- Supportedcites [18] Zeng MY, Immunity 44, 647– 658 (2016). 26944199 PMC4794373 source
The clause the citation is offered for is the background fact that mucosal translocation of gut bacteria is what induces an IgG response against commensal bacteria; the 'preferentially occur in Rs' inference is the citing authors' own conclusion from their FMT data and is not attributed content. Our copy states exactly that mechanism: the Results section 'Homeostatic Induction of Systemic IgG to Gram-Negative Symbiotic Bacteria' concludes that a selective group of gram-negative symbiotic bacteria breach the intestinal epithelial barrier and disseminate systemically to induce IgG, backed by detection of bacterial 16S rRNA in spleens/MLNs and Enterobacteriaceae being the predominant translocated families, and the Introduction/Discussion describe translocation-driven systemic IgG to symbiotic (commensal) bacteria. The only slippage is contextual — Zeng et al. studied resident murine symbionts under homeostatic conditions, not donor/transplanted bacteria or FMT responders — but the mechanism attributed to this source is stated there. (LLM, conf=0.82)
hedgedstates a possible causen = 6- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“administration of certain gut commensals or fecal microbiota transplantation (FMT) promotes anti–PD-1 efficacy in melanoma-bearing mice (10–12).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Partly supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 sourceExperimental — accuracy not yet measured
The paper’s FMT experiments (Fig. 4G–I; page unavailable) report reduced tumor growth and improved response to anti-PD-L1 therapy in mice receiving stool from patients who responded to anti-PD-1, compared with stool from nonresponders. Our copy does not report administering individual gut commensals to mice or testing anti-PD-1 efficacy in those mice. (LLM, conf=0.90)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
In the indexed copy (section labeled Abstract; no page given), fecal transfer from responding patients improved tumor control in melanoma-bearing mice, and anti–PD-L1 treatment was effective in mice colonized with responder microbiota. The mouse experiment tested anti–PD-L1, not anti–PD-1; the copy also does not show that administering individual commensal species improved checkpoint-treatment efficacy in those mice. (LLM, conf=0.88)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In mice, composition of the gut microbiome modulates therapeutic activity of anti–PD-1 and anti–programmed death-ligand 1 (PD-L1)”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Abstract
What the sources say
- Supportedcites [10] Gopalakrishnan V, Science 359, 97– 103 (2018). 29097493 PMC5827966 source
The mouse FMT experiments (Results, Fig. 4G–I passage) state that germ-free mice transplanted with stool from anti–PD-1 responders had significantly reduced tumor growth (p=0.04) versus NR-FMT recipients, and that 'mice transplanted with R-FMT also exhibited improved responses to anti-PD-L1 therapy (Fig. 4I) in contrast to mice that were transplanted with stool from NR (NR-FMT)' — i.e. microbiome composition modulated therapeutic activity of both agents in mice. The abstract likewise reports enhanced anti-tumor immunity 'in germ-free mice receiving fecal transplants from responding patients,' and the closing discussion generalizes to modulation of anti–PD-1 response. The claim's mouse-only scope matches what the paper demonstrates causally in mice. (LLM, conf=0.87)
- Partly supportedcites [11] Matson V, Science 359, 104– 108 (2018). 29302014 PMC6707353 sourceExperimental — accuracy not yet measured
Our copy supports the anti–PD-L1 half of the claim with the paper's own in vivo data: in germ-free mice reconstituted with fecal material from responder versus nonresponder patients, 'Anti–PD-L1 was markedly efficacious in mice colonized with R microbiota yet completely ineffective in NR-derived mice (Fig. 3F)' (Results, Abstract section), and the Abstract states reconstitution with responder feces gave 'greater efficacy of anti-PD-L1 therapy'. However, this study did not administer anti–PD-1 to mice — its patient-level anti–PD-1 association is clinical (42 metastatic melanoma patients), and the mouse evidence for microbiome modulation of anti–PD-1 is explicitly credited to other work: 'Two additional studies have identified an association of the commensal microbiome with anti–PD-1 mAb efficacy in different solid cancers (7,14)... fecal transfer from R versus NR patients to GF mice was also able to recapitulate the patient phenotype' (Discussion). The intro likewise frames the mouse microbiome/anti–PD-L1 precedent as preclinical studies of reference (4). The attribution of the anti–PD-1-in-mice component to this source is therefore not supported by it. (LLM, conf=0.80)
- Not checked yetcites [12] Routy B, Science 359, 91– 97 (2018). 29097494 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
None of the sources cited for this claim have been checked yet.
In the paper
“Multiple circulating cytokines and chemokines decreased after FMT in Rs, including CCL2 (MCP1), CXCL8 (IL-8), and IL-18 that have been associated with negative outcomes to anti–PD-1 (32, 33), and IL-12p70 and IFN-γ (Fig. 4A, heatmap).”
§ Fecal microbiota transplant overcomes resistance to anti–PD-1 therapy in melanoma patients > Fecal microbiota transplant alters serum metabolome and cytokines in responders
What the sources say
- Could not verifycites [32] Gok Yavuz B, Sci. Rep 9, 3172 (2019). 30816272 PMC6395633 sourceExperimental — accuracy not yet measured
Our copy of Yavuz et al. (2019) is an in vitro study of cancer-associated fibroblasts educating CD14+ monocytes/macrophages from healthy donors; it contains no FMT cohort, no patient serum cytokine measurements, and no statement about CCL2/MCP-1, CXCL8/IL-8 or IL-18 levels changing after treatment or being associated with anti-PD-1 outcomes. The closest passages are the Results section 'Recruitment of monocytes by CAFs might be mediated by MCP-1 as well as SDF-1 cytokines' (blocking MCP-1 reduced monocyte migration in vitro) and the Discussion on PD-1+ TAMs citing Gordon et al. and Topalian et al., neither of which addresses circulating cytokine change or immunotherapy outcome association. Searched: 'CCL2 MCP-1 CXCL8 IL-18 negative outcomes anti-PD-1' and 'fecal microbiota transplantation responders serum cytokines' — no supporting passage. (LLM, conf=0.75)
- Not checked yetcites [33] Terme M, Cancer Res. 71, 5393– 5399 (2011). 21724589 source
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Could not verify
28 more claims
Create a free account to see all 56 claims and to verify the 17 references still open.
- Probably not a substantial claim. 5
- It may state two separate claims as one. 21
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Moreover, in several cohorts of patients with melanoma, the clinical response to anti-PD-1 antibodies correlated with the expression of the CUTC gene170 in the faecal microbiome40,91,128.”
From Gut OncoMicrobiome Signatures (GOMS) as next-generation biomarkers for cancer immunotherapy (2023) · cites this paper as [128]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In two proof-of-concept trials with a total of 26 patients, responder-derived fecal microbiota transplantation (FMT) overcame PD-1 resistance in a third of patients with melanoma, suggesting that microbiome modulation could improve responsiveness to anti-PD-1 ICB10,11.”
From Intestinal microbiota signatures of clinical response and immune-related adverse events in melanoma patients treated with anti-PD-1 (2022) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This concurs with another clinical trial with a similar FMT-ICB design in which Akk was also associated with response to ICB post-FMT (Davar et al., 2021).”
From Microbiota triggers STING-type I IFN-dependent monocyte reprogramming of the tumor microenvironment (2021) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Similarly, Davar et al. (2021) found that combining FMT with anti-PD-1 therapy in refractory melanoma patients led to meaningful changes in gut microbial composition, increased activation of CD8+ natural killer-like T cells, recirculation of mucosa-associated invariant T cells, and distinct metabolic shifts associated with enhanced antitumor responses.”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Davar et al., 2021
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The results of two phase 1 clinical studies NCT03341143 and NCT03353402 showed responder-derived FMT effectively relieved the resistance to α-PD-1/PD-L1 in some melanoma patients, having implications for modulating gut microbiota in cancer immunotherapy [26, 317].”
From Combination strategies with PD-1/PD-L1 blockade: current advances and future directions (2022) · cites this paper as [26]
Experimental — accuracy not yet measured
33 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Trimmomatic: a flexible trimmer for Illumina sequence data
Bolger, A. M., Lohse, M., & Usadel, B. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu170 · Cited by 65,548
Fast gapped-read alignment with Bowtie 2
Langmead, B., & Salzberg, S. L. (2012) · Nature Methods · doi:10.1038/nmeth.1923 · Cited by 56,400
Cytoscape: A software Environment for integrated models of biomolecular interaction networks
Shannon, P., Markiel, A., Ozier, O., Baliga, N. S., Wang, J. T., Ramage, D., Amin, N., Schwikowski, B., & Ideker, T. (2003) · Genome Research · doi:10.1101/gr.1239303 · Cited by 51,888
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)
Eisenhauer, E. A., Therasse, P., Bogaerts, J., Schwartz, L. H., Sargent, D., Ford, R., Dancey, J., Arbuck, S., Gwyther, S., Mooney, M., et al. (2009) · European Journal of Cancer · doi:10.1016/j.ejca.2008.10.026 · Cited by 29,534
Prokka: rapid prokaryotic genome annotation
Seemann, T. (2014) · Bioinformatics · doi:10.1093/bioinformatics/btu153 · Cited by 18,818
Metagenomic biomarker discovery and explanation
Segata, N., Izard, J., Waldron, L., Gevers, D., Miropolsky, L., Garrett, W. S., & Huttenhower, C. (2011) · Genome Biology · doi:10.1186/gb-2011-12-6-r60 · Cited by 16,192
Comprehensive Integration of Single-Cell Data
Stuart, T., Butler, A., Hoffman, P., Hafemeister, C., Papalexi, E., Mauck, W. M., Hao, Y., Stoeckius, M., Smibert, P., & Satija, R. (2019) · Cell · doi:10.1016/j.cell.2019.05.031 · Cited by 15,453
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Complex heatmaps reveal patterns and correlations in multidimensional genomic data
Gu, Z., Eils, R., & Schlesner, M. (2016) · Bioinformatics · doi:10.1093/bioinformatics/btw313 · Cited by 10,034
Cited by
Items 501–600 of 1,002
Yang, S., Zhao, S., Ye, Y., Jia, L., & Lou, Y. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.952546 · Cited by 32
“Compared with previous studies (24–26, 31, 32), which mainly focused on the relationship between GM and CI outcomes, the mechanism research of the GM/CI correlation from the perspective of metabolism (44, 59) and immunity (60–62) and the intervention research that alter the GM to improve the efficacy of CI, such as FM…”
BackgroundResultInfluentialPerry, L. M., Cruz, S. M., Kleber, K. T., Judge, S. J., Darrow, M. A., Jones, L. B., Basmaci, U. N., Joshi, N., Settles, M. L., Durbin-Johnson, B. P., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-004285 · Cited by 30
Microbial metabolites and immunotherapy: Basic rationale and clinical indications
Kovtonyuk, L. V., & McCoy, K. D. (2023) · Seminars in Immunology · doi:10.1016/j.smim.2023.101755 · Cited by 27
A narrative review from gut to lungs: non-small cell lung cancer and the gastrointestinal microbiome
Shah, H., & Ng, T. L. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-595 · Cited by 27
“…to ICI to begin with (i.e., non-responders), led to a significant subset of these non-responding patients to become sensitized to the same ICI treatment, thereby demonstrating proof-of-concept that fecal microbiota transplant can modulate the systemic and tumor immune milieu in humans (35,36).”
Wang, S., Xu, B., Zhang, Y., Chen, G., Zhao, P., Gao, Q., & Yuan, L. (2023) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2023.0376 · Cited by 32
“…downregulating the expression of circulating cytokines and chemokines associated with anti-PD-1 antibody resistance, such as CCL2, CXCL8 (IL-8), and IL-18, and upregulating IL-21, CXCL13, IL-10, IL-5, IL-13, TNF, CX3CL1 and FLT3L circulating biomarkers associated with a good clinical response 104 .”
BackgroundPrecision Probiotic Medicine to Improve ICB Immunotherapy
Luccia, B. D., & Colonna, M. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0221 · Cited by 24
Gut dysbiosis in oncology: a risk factor for immunoresistance
(2026) · doi:10.1038/s41422-025-01212-6 · Cited by 24
“232 The persistence of engraftment was supported by follow-up studies showing recurrence of dysbiosis and clinical relapse after antibiotic use, which was also subsequently corrected with a second FMT. 233 Together, these studies indicate that FMT is not a static transfer of taxa but a dynamic…”
InfluentialMessaoudene, M., Ferreira, S., Saint-Lu, N., Ponce, M., Truntzer, C., Boidot, R., Le Bescop, C., Loppinet, T., Corbel, T., Féger, C., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-52373-8 · Cited by 24
Bypassing anti-PD-(L)1 therapy: Mechanisms and management strategies
Mortezaee, K., Majidpoor, J., Najafi, S., & Tasa, D. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.114150 · Cited by 27
The gut microbiota: an emerging modulator of drug resistance in hepatocellular carcinoma
Yao, J., Ning, B., & Ding, J. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2473504 · Cited by 28
Eslami, M., Adampour, Z., Dowlat, B. F., Yaghmayee, S., Tabaei, F. M., Oksenych, V., & Naderian, R. (2025) · Biomedicines · doi:10.3390/biomedicines13040915 · Cited by 31
“These results underscore the potential of FMT to overcome resistance to immune checkpoint inhibitors by reprogramming the gut–immune axis [102].”
Systems Human Immunology and AI: Immune Setpoint and Immune Health
Lei, Y., & Tsang, J. S. (2025) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090122-042631 · Cited by 31
Wang, L., Jiang, W., Yang, M., Danzeng, Q., Liu, S., & Cui, M. (2025) · Cell Communication and Signaling · doi:10.1186/s12964-025-02275-z · Cited by 29
“For instance, results from a phase II clinical trial have indicated that FMT restored microbiota diversity in patients with PD-1-refractory melanoma and dramatically improved the safety and responsiveness to ICIs [21].”
Microbiome Modulation for the Treatment of Solid Neoplasms
Barragán-Carrillo, R., Zengin, Z. B., & Pal, S. K. (2025) · Journal of Clinical Oncology · doi:10.1200/jco-25-00374 · Cited by 33
“On the other hand, Davar et al 46 included exclusively patients with anti – PD-1-refractory metastatic melanoma.”
Sucralose Consumption Ablates Cancer Immunotherapy Response through Microbiome Disruption
Morder, K. M., Nguyen, M., Wilfahrt, D. N., Dahmani, Z. L., Burr, A. B. P., Xie, B., Morikone, M., Nieves-Rosado, H. M., Gunn, W. G., Hurd, D. E., et al. (2025) · Cancer Discovery · doi:10.1158/2159-8290.cd-25-0247 · Cited by 30
“Therapeutic FMTs from responder patients or healthy donors have shown great promise as a therapeutic option in conjunction with anti–PD-1 to patients with resistant or refractory melanomas (51, 52).”
Self-citationThe microbiome, gastrointestinal cancer, and immunotherapy
Newsome, R. C., Yang, Y., & Jobin, C. (2021) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.15742 · Cited by 28
Kundu, P., Stagaman, K., Kasschau, K. D., Holden, S. J., Shulzhenko, N., Sharpton, T. J., & Raber, J. (2022) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2022.791128 · Cited by 24
“A subset of melanoma patients resistant to immunotherapy therapy with anti-PD1 became sensitive to immunotherapy following fecal microbiota transplantation from responsive melanoma patients, indicating that in that context the genotype of the host might be less critical (Davar and Al, 2021).”
BackgroundEvaluating live microbiota biobanking using an ex vivo microbiome assay and metaproteomics
Zhang, X., Walker, K., Mayne, J., Li, L., Ning, Z., Stintzi, A., & Figeys, D. (2022) · Gut Microbes · doi:10.1080/19490976.2022.2035658 · Cited by 28
“Fecal microbiota transplantation (FMT) has been used to treat recurrent Clostridium difficile infection (CDI), inflammatory bowel diseases (IBD)(4,5) and to overcome resistance to anti-PD1 therapy in melanoma patients.(6,7) Small molecules, prebiotics and dietary components are also being studied in high-throughput in…”
BackgroundImmune checkpoint inhibitors in advanced and recurrent/metastatic cervical cancer
Han, X., Chang, W., & Xia, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.996495 · Cited by 27
“A single-arm clinical trial found that FMT (fecal microbiota transplantation) and anti-PD-1 therapy altered the PD-1 response in selected patients with advanced melanoma resistance by altering the gut microbiota and reprogramming the tumor microenvironment (67).”
MethodCreskey, M., Li, L., Ning, Z., Fekete, E. E. F., Mayne, J., Walker, K., Ampaw, A. A., Ben, R. N., Zhang, X., & Figeys, D. (2022) · PROTEOMICS · doi:10.1002/pmic.202200116 · Cited by 24
“The latter are increasingly implicated in various diseases ranging from gastrointestinal, metabolic diseases to neurological disorders and cancers [6-12].”
BackgroundHow Can the Microbiome Induce Carcinogenesis and Modulate Drug Resistance in Cancer Therapy?
Mendes, I., & Vale, N. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241411855 · Cited by 24
“This investigation has shown that FMT and anti-PD-1 altered the intestinal microbiome and reprogrammed the tumor microenvironment to surmount resistance to anti-PD-1 in a subgroup of PD-1 advanced melanoma [233].”
BackgroundPark, J. S., Gazzaniga, F. S., Kasper, D. L., & Sharpe, A. H. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01075-0 · Cited by 25
“More recently, fecal transplantation has been shown to overcome resistance to anti-PD-1 cancer immunotherapy, suggesting a causal relationship between anti-PD-1 therapy and the gut microbiota in patients 140,141 .”
Impact of the ONCOBIOME network in cancer microbiome research
Zitvogel, L., Derosa, L., Routy, B., Loibl, S., Heinzerling, L., de Vries, I. J. M., Engstrand, L., ONCOBIOME Network, Silva, C. A. C., Barbieri, D., et al. (2025) · Nature Medicine · doi:10.1038/s41591-025-03608-8 · Cited by 23
“…of antibiotics on the efficacy of immune checkpoint blockade (ICB) 3,4 and chimeric antigen receptor (CAR) T cell therapies 5 as well as the early success of fecal microbial transplantation (FMT) and the probiotic Clostridium butyri-cum CBM 588 in patients with cancer undergoing treatment 6–10 .”
Self-citationZorea, J., Motro, Y., Mazor, R. D., Carmi, Y. K., Shulman, Z., Mahajna, J. A., Moran‐Gilad, J., & Elkabets, M. (2023) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-023-02680-7 · Cited by 36
Chang, J. W., Hsieh, J., Tsai, C.-Y., Chiu, H.-Y., Lin, Y.-F., Wu, C., Shen, Y., Hou, M., Chang, C.-Y., Chen, J.-A., et al. (2024) · Biomedical Journal · doi:10.1016/j.bj.2024.100698 · Cited by 27
“Some studies from Western countries have focused on targeting microbiota to improve therapeutic effectiveness, and preliminary data were encouraging [40,41].”
BackgroundAdvances in Nanomaterials for Immunotherapeutic Improvement of Cancer Chemotherapy
Liu, J., Li, B., Li, L., Ming, X., & Xu, Z. P. (2024) · Small · doi:10.1002/smll.202403024 · Cited by 24
Microbiota-Derived Short-Chain Fatty Acids Boost Antitumoral Natural Killer Cell Activity
Pérez, M., Buey, B., Sánchez‐Corral, P., Giraldos, D., & Latorre, E. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13133885 · Cited by 30
Zhang, T., Liu, D., Zhang, Y., Chen, L., Zhang, W., & Sun, T. (2024) · Materials Today Bio · doi:10.1016/j.mtbio.2024.101154 · Cited by 37
“Additionally, Davar et al. reported the first human clinical trial of live bacteria fecal microbiota transplantation (FMT) with living bacteria for anti -PD-1 immunotherapy in patients with metastatic melanoma [2], which showed evidences of clinical benefit in a subset of treated patients.”
BackgroundSalivary Microbiome Relates to Neoadjuvant Immunotherapy Response in OSCC
Wang, X., Liu, Y. T., Ren, J., Liu, H. M., Fu, Q., Yang, Y., Fu, Q. Y., & Chen, G. (2024) · Journal of Dental Research · doi:10.1177/00220345241262759 · Cited by 24
“The gut microbiome, enriched in the phylum Firmicutes (Chaput et al. 2019; Andrews et al. 2021; Davar et al. 2021) has been correlated with favorable responses to ICI-based therapy, whereas the Bacteroidales family (Gopalakrishnan et al. 2018) has been linked to poorer responses.”
Potential of natural products and gut microbiome in tumor immunotherapy
Cao, L., Wang, X., Ma, X., Xu, M., & Li, J. (2024) · Chinese Medicine · doi:10.1186/s13020-024-01032-7 · Cited by 25
Lim, M. Y., Hong, S., & Nam, Y. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1512683 · Cited by 27
New insights into gut microbiota–prostate cancer crosstalk
Laaraj, J., Lachance, G., Bergeron, A., Fradet, Y., Robitaille, K., & Fradet, V. (2025) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2025.03.015 · Cited by 27
Clinical Evidence for Microbiome-Based Strategies in Cancer Immunotherapy: A State-of-the-Art Review
Petrelli, F., Ghidini, A., Dottorini, L., Ghidini, M., Zaniboni, A., & Tomasello, G. (2025) · Medicina · doi:10.3390/medicina61091595 · Cited by 33
“In melanoma, early-phase interventional trials demonstrated that FMT from ICI responders could restore sensitivity to anti–PD-1 therapy in patients who had previously progressed, achieving objective response rates between 20% and 40% [8,9].”
First clinical proof-of-concept that FMT can overcome resistance to ICIs
Elkrief, A., & Routy, B. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00502-3 · Cited by 23
Directing T-Cell Immune Responses for Cancer Vaccination and Immunotherapy
Smith, P. L., Piadel, K., & Dalgleish, A. G. (2021) · Vaccines · doi:10.3390/vaccines9121392 · Cited by 24
von Itzstein, M. S., Gonugunta, A. S., Sheffield, T. Y., Homsi, J., Dowell, J. E., Koh, A. Y., Raj, P., Fattah, F. J., Wang, Y., Basava, V. S., et al. (2022) · Cancers · doi:10.3390/cancers14051327 · Cited by 24
“Indeed, recent studies have shown that fecal microbiota transplants may restore ICI efficacy in cases refractory to cancer immunotherapy [30,31].”
BackgroundMetronomic Chemotherapy in Prostate Cancer
Wysocki, P. J., Lubaś, M. T., & Wysocka, M. L. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11102853 · Cited by 25
“Responding patients demonstrated an increased abundance of taxa known to be associated with response to antiPD-1, increased CD8+ T cell activation, and decreased frequency of interleukin-8-expressing myeloid cells [85].”
BackgroundTargeting Th17 cells in HIV-1 remission/cure interventions
Fert, A., Marchand, L. R., Salinas, T. R. W., & Ancuța, P. (2022) · Trends in Immunology · doi:10.1016/j.it.2022.04.013 · Cited by 25
Gupta, I., Pedersen, S., Vranić, S., & Moustafa, A. A. (2022) · Cancers · doi:10.3390/cancers14122964 · Cited by 26
The Gut Microbiome, Microsatellite Status and the Response to Immunotherapy in Colorectal Cancer
Sillo, T. O., Beggs, A. D., Middleton, G., & Akingboye, A. A. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24065767 · Cited by 28
“These have provided encouraging results, with the transfer of microbiota from responders to non-responders inducing good clinical responses [75,76].”
BackgroundThe Gut Microbiome and Pancreatic Cancer Development and Treatment
Attebury, H., & Daley, D. (2023) · The Cancer Journal · doi:10.1097/ppo.0000000000000647 · Cited by 30
“Two recently completed phase 1 FMT clinical trials (NCT03353402, NCT03341143) evaluated the safety and efficacy of FMT and anti–programmed cell death 1 therapy in refractory melanoma.(73,74) The favorable outcomes of these trials have paved the way for future FMT trials in cancer.”
BackgroundXu, W., Wang, T., Wang, N., Zhang, H., Zha, Y., Ji, L., Chu, Y., & Ning, K. (2023) · Briefings in Bioinformatics · doi:10.1093/bib/bbad178 · Cited by 24
“[28] investigated resistance to anti-PD-1 by altering the gut microbiota and overcoming resistance to anti-PD-1 therapy in melanoma patients by fecal microbiota transplantation.”
BackgroundPotential predictive role of gut microbiota to immunotherapy in HCC patients: a brief review
Muscolino, P., Granata, B., Omero, F., Pasquale, C. D., Campana, S., Calabrò, A., D’Anna, F., Drommi, F., Pezzino, G., Cavaliere, R., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1247614 · Cited by 29
Huang, J., Gong, C., & Zhou, A. (2023) · Therapeutic Advances in Medical Oncology · doi:10.1177/17588359231204854 · Cited by 33
“57,58,63”
Wang, W., Fan, J., Zhang, C., Huang, Y., Chen, Y., Fu, S., & Wu, J. (2024) · Microbiological Research · doi:10.1016/j.micres.2024.127668 · Cited by 25
Newman, N. K., Macovsky, M. S., Rodrigues, R. R., Bruce, A. M., Pederson, J. W., Padiadpu, J., Shan, J., Williams, J., Patil, S. S., Dzutsev, A., et al. (2024) · Nature Protocols · doi:10.1038/s41596-024-00960-w · Cited by 28
Self-citationThe impact of the human gut microbiome on the treatment of autoimmune disease
Nayak, R. R., & Orellana, D. A. (2024) · Immunological Reviews · doi:10.1111/imr.13358 · Cited by 23
“37,38 Larger clinical trials are ongoing to determine whether microbiome-directed therapies in patients may improve checkpoint blockade efficacy.”
Gut Microbiota–Related Biomarkers in Immuno-Oncology
Silva, C. A. C., Fidelle, M., Almonte, A. A., Derosa, L., & Zitvogel, L. (2025) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061124-102218 · Cited by 22
Untangling the web of intratumor microbiota in lung cancer
Liu, W. L., Xu, J., Pi, Z., Chen, Y., Jiang, G., Wan, Y., & Mao, W. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.189025 · Cited by 31
Xin, Y., Peng, G., Song, W., Zhou, X., Huang, X., & Cao, X. (2024) · Frontiers in Genetics · doi:10.3389/fgene.2024.1366131 · Cited by 25
She, J., Sun, L., Yu, Y., Fan, H., Li, X., Zhang, X., Zhuo, X., Guo, M., Liu, J., Liu, P., et al. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2415487 · Cited by 24
“25,26 Rapid advances in sequencing technologies and bioinformatics have deeply promoted our cognition on the connection between gut microbiota and drugs.”
BackgroundCancer microbiota: a focus on tumor-resident bacteria
Vella, G., & Rescigno, M. (2025) · EMBO Reports · doi:10.1038/s44319-025-00482-w · Cited by 26
“FMT, the transfer of fecal bacteria from a healthy donor to a recipient to modulate gut microbiota, has shown promising results in preclinical and clinical cancer settings (Baruch et al, 2021; Davar et al, 2021; Gopalakrishnan et al, 2018; Routy et al, 2018; Wang et al, 2024).”
Chen, L., Li, B.-Y., Zu, M.-H., Reis, R., Kundu, S. C., & Xiao, B. (2025) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2025.06.012 · Cited by 23
Harnessing the microbiome for cancer therapy
Hajjar, R., Mars, R. A. T., & Kashyap, P. (2026) · Nature Reviews Microbiology · doi:10.1038/s41579-025-01268-6 · Cited by 34
Microbiome modulation of tumorigenesis and immune responses
Chen, Y., Fang, Y., Lyu, Z., Tian, Y., Niu, S., Li, Y.-R., & Yang, L. (2026) · Journal of Biomedical Science · doi:10.1186/s12929-025-01208-9 · Cited by 30
“Two recent clinical trials in melanoma provided the proof-of-concept that FMT can induce ICB responses: a subset of PD-1-refractory melanoma patients achieved tumor regression or disease stabilization after receiving FMT from a donor who had responded to anti-PD-1 [250, 251].”
Shoji, F., Yamashita, T., Kinoshita, F., Takamori, S., Fujishita, T., Toyozawa, R., Ito, K., Yamazaki, K., Nakashima, N., & Okamoto, T. (2022) · BMJ Open · doi:10.1136/bmjopen-2022-061674 · Cited by 24
Emerging evidence of immunotherapy for colorectal cancer
Miyamoto, Y., Ogawa, K., Ohuchi, M., Tokunaga, R., & Baba, H. (2022) · Annals of Gastroenterological Surgery · doi:10.1002/ags3.12633 · Cited by 29
Zeng, Y., Shi, Q., Liu, X., Tang, H. T., Lu, B., Zhou, Q., Xu, Y., Chen, M., Zhao, J., Li, Y., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1144534 · Cited by 26
“Indeed, patients treated with antibiotics have been shown to have worse outcomes from ICI treatment, and fecal microbiota transplantation (FMT) from responders has been shown to enhance the antitumor effects of anti-PD-1 therapy in both murine models and patients (7, 12, 13).”
BackgroundCrosstalk between gut microbiota and RNA N6-methyladenosine modification in cancer
Su, H., Cheung, H., Lau, H. C.-H., Chen, H., Zhang, X., Wang, Y., Wang, Y., Chan, M. T. V., Wu, W. K. K., & Chen, H. (2023) · FEMS Microbiology Reviews · doi:10.1093/femsre/fuad036 · Cited by 25
From the Colon to the Liver: How Gut Microbiota May Influence Colorectal Cancer Metastatic Potential
Mignini, I., Piccirilli, G., Galasso, L., Termite, F., Esposto, G., Ainora, M. E., Gasbarrini, A., & Zocco, M. A. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13020420 · Cited by 26
“Other clinical trials by Baruch et al. [130] and Davar et al. [131] observed good tolerance for the combination (FMT + ICI), clinical benefit in a subset of treated patients, and the induction of durable microbiota changes, with an increased abundance of taxa previously shown to be associated with…”
BackgroundSun, Y., Zhou, J., Du, H., Zhou, Z. C., Han, Y., Luo, M., Guo, X., Gu, M., Yang, H., & Xiao, H. (2024) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c07935 · Cited by 22
Gut microbiota and immunosenescence in cancer
Xu, Y., He, C., Xi, Y., Zhang, Y., & Bai, Y. (2024) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2024.07.004 · Cited by 24
Autoimmune Responses in Oncology: Causes and Significance
Bareke, H., Juanes‐Velasco, P., Landeira‐Viñuela, A., Hernández, Á., Cruz, J. J., Bellido, L., Fonseca, E., Cárdenas, A. N., Montalvillo, E., Góngora, R., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22158030 · Cited by 27
“Recently, a clinical trial was conducted wherein fecal microbiota transplant (FMT) was performed on metastatic melanoma patients who were refractory to anti PD-1 therapy [63].”
BackgroundMethodGut bacteria enable prostate cancer growth
McCulloch, J. A., & Trinchieri, G. (2021) · Science · doi:10.1126/science.abl7070 · Cited by 21
Self-citationMicrobiota in Health and Disease—Potential Clinical Applications
Laudes, M., Geisler, C., Rohmann, N., Bouwman, J., Pischon, T., & Schlicht, K. (2021) · Nutrients · doi:10.3390/nu13113866 · Cited by 25
“FMT lead to clinical benefit in 6 out of 15 cases and also resulted in rapid and durable microbiota perturbation [46].”
BackgroundFecal Microbiota Transplant for Hematologic and Oncologic Diseases: Principle and Practice
Zerdan, M. B., Niforatos, S., Nasr, S., Nasr, D., Ombada, M., John, S., Dutta, D., & Lim, S. H. (2022) · Cancers · doi:10.3390/cancers14030691 · Cited by 28
“Three of the ten patients in one study restored the response to immunotherapy following FMT [72], and 6 of 15 in another study showed clinical benefits [73].”
BackgroundGut Microbiota and Immunotherapy
Xu, X., & Ying, J. (2022) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.945887 · Cited by 25
Harnessing Bacterial Extracellular Vesicle Immune Effects for Cancer Therapy
Karaman, İ., Pathak, A., Bayık, D., & Watson, D. C. (2024) · Pathogens and Immunity · doi:10.20411/pai.v9i1.657 · Cited by 20
Čierniková, S., Ševčíková, A., Novisedláková, M., & Mego, M. (2024) · Cancers · doi:10.3390/cancers16244271 · Cited by 24
“The recipients’ gut microbiomes shifted to resemble the donors’ profile, with notable increases in the abundances of Lach-nospiraceae , Ruminococcaceae , Bifidobacteriaceae , and Coriobacteriaceae , together with a decrease in members of the Bacteroidetes phylum [118].”
Lu, G., Zhang, S., Wang, R., Wu, X., Chen, Y., Wen, Q., Cui, B., Zhang, F., & Li, P. (2025) · BMC Medicine · doi:10.1186/s12916-025-04353-y · Cited by 25
“…domains in clinical practice, including gastrointestinal disorders[35, 36], infections[37, 38], metabolic disorders[39], microbiota-gut-liver axis[40], microbiota-gut brain axis[41], oncology[42, 43], hematological disorders[44], and other diseases[45] such as chronic obstructive pulmonary disease.”
Self-citationThe microbiome as a therapeutic co-driver in melanoma immuno-oncology
Bautista, J., Chávez, J. A. V., Larco, D. S. B., Martín-Aguilera, R., & López‐Cortés, A. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1673880 · Cited by 28
“These insights have catalyzed the development of microbiome-targeted interventions, including fecal microbiota transplantation (FMT), which has shown promise in restoring immunotherapeutic responses in melanoma patients resistant to ICIs (8, 11).”
InfluentialAldriwesh, M. G., Alotibi, R. S., Alqurainy, N., Alrabiah, S., Arafah, A. M., Alghoribi, M. F., & Ajina, R. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2607076 · Cited by 24
Cancer ecosystems: A dynamic interplay across scales
Quail, D. F., & Joyce, J. A. (2026) · Cell · doi:10.1016/j.cell.2026.03.003 · Cited by 30
Commensal Bifidobacterium Strains Enhance the Efficacy of Neo-Epitope Based Cancer Vaccines
Tomasi, M., Dalsass, M., Beghini, F., Zanella, I., Caproni, E., Fantappiè, L., Gagliardi, A., Irene, C., König, E., Frattini, L. F., et al. (2021) · Vaccines · doi:10.3390/vaccines9111356 · Cited by 21
“Moreover, transplantation of fecal microbiome from patients responding to PD-L1 therapy, but not from non-responders, improves the efficacy of checkpoint inhibitors both in animal models and in melanoma patients [4,7,8].”
BackgroundThe cure from within? a review of the microbiome and diet in melanoma
Kumar, P. R., Brazel, D., DeRogatis, J. M., Goldstein, J. B., Whiteson, K., Chow, W. A., Tinoco, R., & Moyers, J. T. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10029-3 · Cited by 25
Clostridioides difficile infection in cancer patients receiving immune checkpoint inhibitors
Vasavada, S. R., Panneerselvam, K., Amin, R., Varatharajalu, K., Okhuysen, P. C., Oliva, I. C. G., Wang, J., Grivas, P., Thomas, A. S., & Wang, Y. (2022) · Annals of Gastroenterology · doi:10.20524/aog.2022.0722 · Cited by 22
Gut Microbiota and Immunotherapy for Alzheimer’s Disease
Dai, C., Liu, F., Iqbal, K., & Gong, C. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms232315230 · Cited by 25
“Importantly, FMT from responder patients overcomes resistance to anti-PD-1 therapy in melanoma patients [164].”
BackgroundThe impact of microbiome dysbiosis on T cell function within the tumor microenvironment (TME)
DiPalma, M. P., & Blattman, J. N. (2023) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2023.1141215 · Cited by 23
“Strikingly, more recent investigations have shown fecal transplants from ICB responders to non-responders for melanoma treatment saw that more than one-third of human patients previously unresponsive to treatment become responsive after transplants (Davar et al., 2021).”
BackgroundDiet-gut microbial interactions influence cancer immunotherapy
Wang, X., & Geng, S.-T. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1138362 · Cited by 23
Gut and urinary microbiota: the causes and potential treatment measures of renal cell carcinoma
Yang, J.-W., Wan, S., Li, K., Chen, S., & Yang, L. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1188520 · Cited by 26
“melanoma patients, and it is exciting to note that among the enrolled cohort of 16 melanoma patients who exhibited resistance to anti–PD-1 therapy and received adjunctive FMT therapy, three individuals achieved objective responses (OR), while three others experienced sustained stable disease (SD) for over 12 months (7…”
BackgroundDeng, X., Zhang, C., Yang, Y., Wang, J., Ye, X., Gu, J., Zhang, X., & Jin, H. (2023) · Journal of Cancer · doi:10.7150/jca.88854 · Cited by 21
Inhibition of SFTSV replication in humanized mice by a subcutaneously administered anti-PD1 nanobody
Ji, M., Hu, J. L., Zhang, D., Huang, B., Xu, S., Jiang, N., Chen, Y., Wang, Y., Wu, X., & Wu, Z. (2024) · EMBO Molecular Medicine · doi:10.1038/s44321-024-00026-0 · Cited by 20
“PD-1/ PD-L1 is an important inhibitory checkpoint signaling pathway that inhibits immune responses against cancers and viral infections (Davar et al, 2021; Uldrick et al, 2022).”
Li, L., Huang, X., & Chen, H. (2024) · Gut Microbes · doi:10.1080/19490976.2024.2328868 · Cited by 23
Role of gut microbiome in suppression of cancers
Xu, Y., Gao, Z., Liu, J., Yang, Q., & Xu, S. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2495183 · Cited by 21
Precision strategies for cancer treatment by modifying the tumor-related bacteria
Lu, H., Wang, Q., Liu, W., Wen, Z., & Li, Y. (2021) · Applied Microbiology and Biotechnology · doi:10.1007/s00253-021-11491-9 · Cited by 22
Barisic, S., & Childs, R. W. (2022) · Stem Cells · doi:10.1093/stmcls/sxac021 · Cited by 26
Tumor immune microenvironment and systemic response in breast cancer
Kawaguchi, K., Maeshima, Y., & Toi, M. (2022) · Medical Oncology · doi:10.1007/s12032-022-01782-0 · Cited by 22
“Thus, together with the aforementioned data related to gut microbiota in melanoma [28], it can be inferred that the gut microbiota and systemic cytokines are closely associated.”
BackgroundInfluentialMicrobiota-centered interventions to boost immune checkpoint blockade therapies
Almonte, A. A., Thomas, S., & Zitvogel, L. (2025) · Journal of Experimental Medicine · doi:10.1084/jem.20250378 · Cited by 19
Unveiling gut microbiota's role: Bidirectional regulation of drug transport for improved safety
Wang, J., & Zhou, T. (2024) · Medicinal Research Reviews · doi:10.1002/med.22077 · Cited by 22
“139 Fecal microbiota transplantation (FMT) can alter the tumor microenvironment, overcoming resistance to anti ‐ PD ‐ 1 therapy in melanoma, thereby enhancing anticancer immune responses.”
The gut microbiome modulate response to immunotherapy in cancer
Jiang, S., Kang, Z., Chen, Y., & Fang, J. (2024) · Science China Life Sciences · doi:10.1007/s11427-023-2634-7 · Cited by 22
“This treatment was associated with favorable changes in immune cell infiltrates and gene expression profiles in both the gut lamina propria and the tumor microenvironment (Davar et al., 2021).”
Effect of Gut Dysbiosis on Onset of GI Cancers
Kumari, S., Srilatha, M., & Nagaraju, G. P. (2024) · Cancers · doi:10.3390/cancers17010090 · Cited by 23
“FMT combined with anti-PD-1 therapy in 15 patients led to clinical benefits in 6 patients, increasing gut microbiota diversity and CD8 + T cell activation, and decreasing interleukin-8 myeloid cells, demonstrating FMT’s potential to overcome anti-PD-1 resistance (Figure 3) [67].”
Gut microbiota in cancer initiation, development and therapy
Zhang, R., Zhang, X., Lau, H. C.-H., & Yu, J. Q. (2024) · Science China Life Sciences · doi:10.1007/s11427-024-2831-x · Cited by 19
“Similarly, two small clinical trials found that FMT from ICB responders, when combined with anti-PD-1 therapy, successfully overcame resistance to PD-1 blockade in patients with refractory melanoma (Baruch et al., 2021; Davar et al., 2021).”
Han, Q., Li, J., Li, Z. Y., Aishajiang, R., & Yu, D. N. (2025) · Materials Today Bio · doi:10.1016/j.mtbio.2025.101601 · Cited by 32
“…by diverse gut microbiota, which are considered to affect the treatment outcomes of patients with CRC. Davar et al. investigated 30 chemotherapy drugs, among which 10 drugs were inhibited by Escherichia coli or Weissella viridescens , whereas six drugs exhibited enhanced antitumor activity [8].”
Gut microbial predictors of first-line immunotherapy efficacy in advanced NSCLC patients
Grenda, A., Iwan, E., Kuźnar-Kamińska, B., Bomba, A., Bielińska, K., Krawczyk, P., Chmielewska, I., Frąk, M., Szczyrek, M., Rolska-Kopińska, A., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-89406-1 · Cited by 28
Interaction between gut microbiota and T cell immunity in colorectal cancer
Jing, Z., Wu, Y., Chu, J., Zhanbo, Q., Wu, X., & Han, S. (2025) · Autoimmunity Reviews · doi:10.1016/j.autrev.2025.103807 · Cited by 20
Combinational therapeutic strategies to overcome resistance to immune checkpoint inhibitors
Al-Saafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1546717 · Cited by 27
Intestinal and esophageal microbiota in esophageal cancer development and treatment
Baba, Y., Tajima, K., & Yoshimura, K. (2025) · Gut Microbes · doi:10.1080/19490976.2025.2505118 · Cited by 22
Gronich, N., Geva‐Zatorsky, N., Herren, R., Kelly, L., Cohen, Z., Zhou, H., Chen, Y. H., Shah, K., Robinson‐Catala, T. A., Frisby, G., et al. (2025) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.70066 · Cited by 26
“80,81 Moreover, extensive clinical studies have evaluated the effects of microbial metabolite supplementation in immunotherapy, including SCFAs, tryptophan metabolites, inosine, TMAO, and vitamin B5.”
Wang, X., Xiong, D., Cui, S., Duan, B., Ding, G., Huang, Y., & Wang, Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1732079 · Cited by 29
Kleber, K. T., Iranpur, K. R., Perry, L. M., Cruz, S. M., Razmara, A. M., Culp, W. T. N., Kent, M. S., Eisen, J. A., Rebhun, R. B., & Canter, R. J. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.983344 · Cited by 23
“demonstrated that response to checkpoint immunotherapies may be conferred or eliminated through gut microbiome modulation (7, 8).”
Background
Metadata
- Authors
- Davar, D., Dzutsev, A. K., McCulloch, J. A., Rodrigues, R. R., Chauvin, J.-M., Morrison, R. M., Deblasio, R. N., Menna, C., Ding, Q., Pagliano, O., Zidi, B., Zhang, S., Badger, J. H., Vetizou, M., Cole, A. M., Fernandes, M. R., Prescott, S., Costa, R. G. F., Balaji, A. K., Morgun, A., Vujkovic-Cvijin, I., Wang, H., Borhani, A. A., Schwartz, M. B., Dubner, H. M., Ernst, S. J., Rose, A., Najjar, Y. G., Belkaid, Y., Kirkwood, J. M., Trinchieri, G., & Zarour, H. M.
- Affiliations
- University of Pittsburgh (US)
- National Cancer Institute (US)
- Frederick National Laboratory for Cancer Research (US)
- Department of Medicine and UPMC Hillman Cancer Center, University of Pittsburgh, Pittsburgh, PA 15213, USA.
- Laboratory of Integrative Cancer Immunology, Center for Cancer Research, National Cancer Institute, Bethesda, MD 20892, USA.
- Oregon State University (US)
- National Institutes of Health (US)
- Corresponding author
- Davar, Diwakar
- Dzutsev, Amiran K.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- ORCID
- Davar, Diwakar
- Dzutsev, Amiran K.
- McCulloch, John A.
- Rodrigues, Richard R.
- Chauvin, Joe-Marc
- Morrison, Robert M.
- Pagliano, Ornella
- Zidi, Bochra
- Zhang, Shuowen
- Badger, Jonathan H.
- Vetizou, Marie
- Cole, Alicia M.
- Fernandes, Miriam R.
- Prescott, Stephanie
- Costa, Raquel G. F.
- Balaji, Ascharya K.
- Morgun, Andrey
- Vujkovic-Cvijin, Ivan
- Wang, Hong
- Borhani, Amir A.
- Schwartz, Marc B.
- Dubner, Howard M.
- Najjar, Yana G.
- Belkaid, Yasmine
- Kirkwood, John M.
- Trinchieri, Giorgio
- Zarour, Hassane M.
- Venue
- Science
- Published
- 2021-02-05
- Volume
- 371
- Issue
- 6529
- Pages
- 595-602
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- PMC
- PMC8097968
- OpenAlex
- W3126208996
- Cited by
- 1,781
- References
- 54
- Citations by year
- 2026: 396 · 2025: 328 · 2024: 315 · 2023: 316 · 2022: 282 · 2021: 141
- FWCI
- 97.40
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Cancer Institute (CA228181, CA222203)
- Melanoma Research Foundation (MRFBC 2020)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- fecal microbiota transplantation, anti-PD-1 therapy, melanoma, immunotherapy resistance, gut microbiota, CD8+ T cell activation, interleukin-8, myeloid cells, immunosuppression
- MeSH terms
- Gastrointestinal Microbiome, Fecal Microbiota Transplantation, Antineoplastic Agents, Immunological, Humans, Lymphocyte Activation, Melanoma, Skin Neoplasms, Interleukin-8, Lymphocytes, Tumor-Infiltrating, CD8-Positive T-Lymphocytes, Drug Resistance, Neoplasm, Myeloid Cells, Tumor Microenvironment, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-05, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-05 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (qwen3.8-omni-flash and gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.